frontiermeds.comHealthcare / BioTech & PharmaFounded: 2018Funding to Date: $511MM
Frontier Medicines is a precision medicine company that develops breakthrough medicines for patients. Specifically, the company focuses on developing therapies for previously undruggable disease-causing proteins. Through its proprietary Frontier Platform, the company combines scientific approaches that include chemoproteomics, covalent drug discovery, and machine learning. Frontier Medicines was founded in 2018 by Chris Varma Ph.D and headquartered in San Francisco, CA.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
06/25/2024 | Series C | $100MM | $xx.xx | $438.18MM | Arrowmark Partners, Dcvc, Deep Track Capital, Deerfield Management Company, Droia Ventures, Galapagos Nv, Mpm Capital, Ra Capital Management | |
Price per Share
$xx.xx
Shares Outstanding
42,746,002
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
2
Key Investors
Arrowmark Partners, Dcvc, Deep Track Capital, Deerfield Management Company, Droia Ventures, Galapagos Nv, Mpm Capital, Ra Capital Management
|
||||||
07/19/2021 | Series B | $88.5MM | $xx.xx | $416.96MM | Arrowmark Partners, Dcvc, Deep Track Capital, Deerfield Management Company, Driehaus Capital Management, Droia Ventures, Mpm Capital, Ra Capital Management, Sphera Healthcare, Woodline Partners Lp | |
Price per Share
$xx.xx
Shares Outstanding
33,007,598
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
2
Key Investors
Arrowmark Partners, Dcvc, Deep Track Capital, Deerfield Management Company, Driehaus Capital Management, Droia Ventures, Mpm Capital, Ra Capital Management, Sphera Healthcare, Woodline Partners Lp
|
||||||
06/25/2019 | Series A-1 | $33.5MM | $xx.xx | $167.5MM | Berkeley Catalyst Fund, Dcvc, Deerfield Management, Droia Oncology Ventures, Mpm Capital, Ra Capital Management | |
Price per Share
$xx.xx
Shares Outstanding
33,500,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
2
Key Investors
Berkeley Catalyst Fund, Dcvc, Deerfield Management, Droia Oncology Ventures, Mpm Capital, Ra Capital Management
|
||||||
06/25/2019 | Series A-2 | $33.5MM | $xx.xx | $167.5MM | Berkeley Catalyst Fund, Dcvc, Deerfield Management, Droia Oncology Ventures, Mpm Capital, Ra Capital Management | |
Price per Share
$xx.xx
Shares Outstanding
26,800,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
2
Key Investors
Berkeley Catalyst Fund, Dcvc, Deerfield Management, Droia Oncology Ventures, Mpm Capital, Ra Capital Management
|